van den Heuvel, L. P., van de Kar, N. C. A. J., Duineveld, C., Sarlea, A., van der Velden, T. J. A. M., Liebrand, W. T. B., . . . Volokhina, E. B. (2020). The complement component C5 is not responsible for the alternative pathway activity in rabbit erythrocyte hemolytic assays during eculizumab treatment. Cell Mol Immunol.
Citação norma Chicagovan den Heuvel, Lambertus P., et al. "The Complement Component C5 Is Not Responsible for the Alternative Pathway Activity in Rabbit Erythrocyte Hemolytic Assays During Eculizumab Treatment." Cell Mol Immunol 2020.
Citação norma MLAvan den Heuvel, Lambertus P., et al. "The Complement Component C5 Is Not Responsible for the Alternative Pathway Activity in Rabbit Erythrocyte Hemolytic Assays During Eculizumab Treatment." Cell Mol Immunol 2020.